What is 3D BioFibR?
3D BioFibR operates at the intersection of synthetic biology and material science, specializing in the manufacturing of naturally sourced, high-value fibers. The company's core product portfolio includes spider silk, collagen, and chitosan, which are engineered to meet the rigorous demands of various industrial and medical applications. By utilizing advanced bio-fabrication techniques, 3D BioFibR provides sustainable, high-performance alternatives to traditional materials, positioning itself as a key player in the burgeoning bio-economy. Its location in Canada provides a strategic advantage, allowing it to tap into a robust ecosystem of innovation and research-driven growth.
How much funding has 3D BioFibR raised?
3D BioFibR has raised a total of $7.8M across 4 funding rounds:
Angel/Seed
$550K
Other Financing Round
$700K
Other Financing Round
$3.5M
Private Equity
$3M
Angel/Seed (2020): $550K with participation from Undisclosed
Other Financing Round (2021): $700K led by Concrete Ventures and Globalive Capital
Other Financing Round (2023): $3.5M supported by Build Ventures and Concrete Ventures
Private Equity (2025): $3M featuring AO Foundation, Invest Nova Scotia, Build Ventures, and Concrete Ventures
Key Investors in 3D BioFibR
Build Ventures
Build Ventures is a venture capital firm based in Halifax, Nova Scotia, that specializes in providing early stage capital to technology companies in Atlantic Canada.
Concrete Ventures
Concrete Ventures is an Atlantic Canadian pre-seed venture capital fund that partners with innovative founders to help them build scalable businesses.
AO Foundation
A medically guided nonprofit organization led by an international group of surgeons specialized in the treatment of trauma and disorders of the musculoskeletal system.
What's next for 3D BioFibR?
With the recent influx of capital, 3D BioFibR is poised to scale its manufacturing infrastructure to meet increasing demand for its biomaterial solutions. The strategic involvement of medical-focused entities like the AO Foundation suggests a clear roadmap toward clinical-grade applications, potentially disrupting the orthopedic and trauma care markets. Moving forward, the company will likely focus on optimizing its production efficiency and securing further commercial partnerships to solidify its market position. As it moves beyond the initial scaling phase, the focus will shift toward long-term sustainability and the commercialization of its proprietary fiber technology on a global scale.
See full 3D BioFibR company page
